Company Eurofins Cerep Euronext Paris
Equities
FR0012045946
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
30/04 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Business Summary
Exports account for 94.2% of net sales.
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Preclinical Drug Research Services
100.0
%
| 48 | 100.0 % | 44 | 100.0 % | -7.47% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
International
94.2
%
| 47 | 97.7 % | 41 | 94.2 % | -10.82% |
France
5.8
%
| 1 | 2.3 % | 3 | 5.8 % | +134.99% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 19/18/19 | |
Damien Séroux
CHM | Chairman | - | 13/14/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Damien Séroux
CHM | Chairman | - | 13/14/13 |
Director/Board Member | 68 | 10/15/10 | |
Chief Executive Officer | - | 19/18/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,044 | 213 ( 4.223 %) | 0 | 4.223 % |
Company contact information
Eurofins-Cerep SA
Le bois l'Evêque
86600, Celle l'Evescault
+33 5 49 89 30 00
http://www.eurofins.fr/cerep/Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ALECR Stock
- Stock
- Company Eurofins Cerep